Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Rattachement africain : gb, pk, sa. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of these emerging agents. A comprehensive literature search was conducted using PubMed, the Cochrane Library, and Google Scholar from inception to June 2025 to identify randomized controlled trials evaluating tirzepatide, retatrutide, or mazdutide in obese adults. Clinical outcomes were assessed using the random-effects model and pooled as mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs). A total of 10 randomized controlled trials, including 3236 participants, were analyzed. Incretin polyagonists significantly reduced body weight compared to placebo (MD -11.47; 95% CI: -14.00 to -8.95). Significant reductions were also observed in waist circumference (MD -9.40; 95% CI: -11.91 to -6.89), glycated hemoglobin (MD -0.96; 95% CI: -1.16 to -0.75), and fasting plasma glucose (MD -26.89 mg/dL; 95% CI: -33.48 to -20.30). However, the use of dual and triple agonists was associated with a higher risk of any adverse events (AEs) (RR 1.13; 95% CI: 1.08-1.19), including gastrointestinal AEs (nausea, vomiting, diarrhea, constipation), AEs leading to withdrawal (RR 1.96; 95% CI: 1.17-3.30), and hypoglycemic episodes (RR 3.08; 95% CI: 1.61-5.89). No significant difference was found in serious AEs (RR 0.87; 95% CI: 0.65-1.14). In conclusion, incretin-based polyagonists were associated with significant weight reduction and improved metabolic outcomes compared to placebo.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
- Date Crossref
- 19/02/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Musgrove Park Hospital Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Aneurin Bevan University Health Board Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Newcastle University Translational and Clinical Research Institute pays non établi dans la noticeUniversité ou école supérieure
-
University Hospitals Plymouth NHS Trust Department of Cardiology pays non établi dans la noticeÉtablissement de santé
-
Nishtar Medical College and Hospital pays non établi dans la noticeInstitution
-
Bolan University of Medical and Health Sciences pays non établi dans la noticeÉtablissement de santé
-
Pakistan Institute of Medical Sciences pays non établi dans la noticeÉtablissement de santé
-
Northumbria Healthcare NHS Foundation Trust Department of Psychiatry pays non établi dans la noticeÉtablissement de santé
-
Sandwell & West Birmingham Hospitals NHS Trust pays non établi dans la noticeÉtablissement de santé
-
The Rotherham NHS Foundation Trust Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
James Cook University Hospital Department of Radiology pays non établi dans la noticeÉtablissement de santé
-
Saudi Aramco Medical Services Organization pays non établi dans la noticeÉtablissement de santé
Department of Cardiology — Musgrove Park Hospital, Department of Medicine — Aneurin Bevan University Health Board et Translational and Clinical Research Institute — Newcastle University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.